UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial

Spathis, A; Fife, K; Blackhall, F; Dutton, S; Bahadori, R; Wharton, R; O'Brien, M; ... Wee, B; + view all (2014) Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. [Rapid communication]. Journal of Clinical Oncology , 32 (18) pp. 1882-1888. 10.1200/JCO.2013.54.4346.

[thumbnail of 2014 Spathis et al.pdf] Text
2014 Spathis et al.pdf
Access restricted to UCL open access staff

Download (166kB)

Abstract

PURPOSE: Fatigue is a distressing symptom occurring in more than 60% of patients with cancer. The CNS stimulants modafinil and methylphenidate are recommended for the treatment of cancer-related fatigue, despite a limited evidence base. We aimed to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Adults with advanced NSCLC and performance status of 0 to 2, who were not treated with chemotherapy or radiotherapy within the last 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo. The primary outcome was change in Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue score from baseline to 28 days, adjusted for baseline fatigue and performance status. Secondary outcomes included safety and patient-reported measures of depression, daytime sleepiness, and quality of life. RESULTS: A total of 208 patients were randomly assigned, and 160 patients (modafinil, n = 75; placebo, n = 85) completed questionnaires at both baseline and day 28 and were included in the modified intention-to-treat analysis. FACIT-Fatigue scores improved from baseline to day 28 (mean score change: modafinil, 5.29; 95% CI, 2.57 to 8.02; placebo, 5.09; 95% CI, 2.54 to 7.65), but there was no difference between treatments (0.20; 95% CI, -3.56 to 3.97). There was also no difference between treatments for the secondary outcomes; 47% of the modafinil group and 23% of the placebo group stated that the intervention was not helpful. CONCLUSION: Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting. Its use was associated with a clinically significant placebo effect.

Type: Article
Title: Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial
Location: United States
DOI: 10.1200/JCO.2013.54.4346
Publisher version: http://dx.doi.org/10.1200/JCO.2013.54.4346
Language: English
Additional information: © 2014 by American Society of Clinical Oncology
Keywords: Aged, Aged, 80 and over, Benzhydryl Compounds, Carcinoma, Non-Small-Cell Lung, Central Nervous System Stimulants, Double-Blind Method, Drug Administration Schedule, Fatigue, Female, Great Britain, Humans, Lung Neoplasms, Male, Methylphenidate, Middle Aged, Placebo Effect, Severity of Illness Index, Treatment Failure, Wakefulness-Promoting Agents
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry
URI: https://discovery.ucl.ac.uk/id/eprint/1432760
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item